Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Show more...
FAQ
Novakand Pharma AB 今天的股價是多少?▼
KAN.ST 目前價格為 SEK0.3 SEK,過去 24 小時下跌了 -3.56%。在圖表上更密切關注 Novakand Pharma AB 股票的表現。
Novakand Pharma AB 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Novakand Pharma AB 的股票以代號 KAN.ST 進行交易。
Novakand Pharma AB 的股價在上漲嗎?▼
KAN.ST 股票較上週上漲 +0%,本月上漲 +0%,但過去一年 Novakand Pharma AB 下跌 -75.37%。
Novakand Pharma AB 去年的營收是多少?▼
Novakand Pharma AB 去年的營收為 0SEK。
Novakand Pharma AB 去年的淨利是多少?▼
KAN.ST 去年的淨收益為 -44.57MSEK。
Novakand Pharma AB 有多少名員工?▼
截至 April 30, 2026,公司共有 5 名員工。
Novakand Pharma AB 位於哪個產業?▼
Novakand Pharma AB從事於Health & Wellness產業。
Novakand Pharma AB 何時完成拆股?▼
Novakand Pharma AB 上次拆股發生於 February 24, 2021,比例為 1:10。
Novakand Pharma AB 的總部在哪裡?▼
Novakand Pharma AB 的總部位於 瑞典 的 Solna。